Cerity Partners
DAWN

Cerity Partners’s Day One Biopharmaceuticals DAWN Stock Holding History

Cerity Partners’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$390K Buy
18,197
+6,611
+57% +$93.2K ﹤0.01% 2433
2025
Q4 		$108K Buy
+11,586
New +$96.8K ﹤0.01% 2736
2025
Q3 		– Sell
-14,417
Closed -$93.7K – 2778
2025
Q2 		$93.7K Sell
14,417
-582
-4% -$4K ﹤0.01% 2490
2025
Q1 		$119K Buy
+14,999
New +$162K ﹤0.01% 2302

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Cerity Partners's DAWN Position: Q1 2026 in Review

Cerity Partners increased its Day One Biopharmaceuticals (DAWN) stake by 57% in Q1 2026, buying an estimated $93.2K and bringing the position to 18,197 shares worth $390K. The position accounts for ﹤0.01% of the portfolio, ranked #2433.

Cerity Partners first reported a position in DAWN in Q1 2025 and has held it in 4 quarters since. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Cerity Partners held 18,197 shares of Day One Biopharmaceuticals worth $390K as of Q1 2026.
  • Cerity Partners bought 6,611 Day One Biopharmaceuticals shares in Q1 2026, an estimated $93.2K.
  • Day One Biopharmaceuticals made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #2433 holding.
  • Cerity Partners first reported a position in Day One Biopharmaceuticals in Q1 2025 and has held it in 4 quarters since.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.